3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
19
Active not recruiting
5
Unknown
4
Terminated
4
Recruiting
2
Withdrawn
1
Suspended
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
1
Interventions
Carboplatin
75
Cisplatin
73
Bevacizumab
64
Radiotherapy
57
Drug Therapy
56
Capecitabine
56
tislelizumab
54
Oxaliplatin
54
Gemcitabine
46
toripalimab
45
Paclitaxel
45
Specimen Handling
43
sintilimab
39
pembrolizumab
39
anlotinib
38
Cyclophosphamide
33
130-nm albumin-bound paclitaxel
32
Magnetic Resonance Spectroscopy
27
Injections
27
camrelizumab
26
Pemetrexed
26
Surgical Procedures, Operative
25
lenvatinib
23
Docetaxel
23
Biopsy
23
apatinib
22
Etoposide
22
Immune Checkpoint Inhibitors
21
S 1 (combination)
20
Fluorouracil
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Not yet recruiting
×
Lomustine
×
Clear all
NCT07120984
2025-08-13
IMAGLIO
Philogen S.p.A.
Phase 2
Not yet recruiting
52 enrolled